載入中
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
前收盤價
US$14.34
+US$0.35 · +2.50%
盤中時間採用ET。市場資料可能有所延遲。
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
日內區間
目前US$14.34
52週區間
目前US$14.34
盤中時間採用ET。市場資料可能有所延遲。
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
日內區間
目前US$14.34
52週區間
目前US$14.34
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 |
|---|---|---|
| 營收 | 3189.3萬 USD | 2045.9萬 USD |
| 毛利 | 3189.3萬 USD | 2045.9萬 USD |
| 研究與開發 | 2.25億 USD | 1.75億 USD |
| 銷售、一般及管理費用 | 4226萬 USD | 4208.7萬 USD |
| 營業費用 | 2.67億 USD | 2.17億 USD |
| 利息收入 | 1366.1萬 USD | 1811.8萬 USD |
| 利息支出 | 113.6萬 USD | 211.8萬 USD |
| 折舊和攤銷 | 1317.8萬 USD | 1534.9萬 USD |
| 營業利益 | −2.35億 USD | −1.97億 USD |
| 淨利 | −2.03億 USD | −1.74億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$26.00
上漲空間 81.31%報告持有此股票曝險的交易所交易基金。
ARK Genomic Revolution ETFARKG2199.06萬1.07%15.57億 USD0.75%US$51.30+4.08%
Vanguard Morningstar Total Stock Market ETFVTI1247.37萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM905.85萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF458.61萬0.00%954億 USD0.05%US$235+0.80%
JPMorgan U.S. Tech Leaders ETFJTEK410.97萬0.08%48.99億 USD0.65%US$107.91+1.80%
ALPS Medical Breakthroughs ETFSBIO233.76萬1.22%1.91億 USD0.50%US$55.04+2.03%
iShares Russell 2000 Growth ETFIWO220萬0.02%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO214.62萬0.01%180億 USD0.06%US$112.66+0.50%ARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFJPMorgan U.S. Tech Leaders ETFJTEKALPS Medical Breakthroughs ETFSBIOiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
